GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (FRA:4GB) » Definitions » Total Receivables

Gossamer Bio (FRA:4GB) Total Receivables : €3.37 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Total Receivables?

Gossamer Bio's Total Receivables for the quarter that ended in Jun. 2024 was €3.37 Mil.


Gossamer Bio Total Receivables Historical Data

The historical data trend for Gossamer Bio's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Total Receivables Chart

Gossamer Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial - - - - -

Gossamer Bio Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 3.37

Gossamer Bio Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Gossamer Bio Total Receivables Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Gossamer Bio Business Description

Traded in Other Exchanges
Address
3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio Headlines

No Headlines